Original Query: ALL
Previous Study | Return to List | Next Study

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01828034
Recruitment Status : Active, not recruiting
First Posted : April 10, 2013
Last Update Posted : October 27, 2017
Array BioPharma
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 2018
  Estimated Study Completion Date : April 2018